Each rhinology tumor case seen at Penn is presented and discussed at a multidisciplinary skull base tumor conference. Specialists from otorhinolaryngology, neurosurgery, pathology, oncology, and radiation oncology meet to share information and develop the best possible treatment plans. This collaborative approach offers the unique benefit of treatment recommendations that are collectively decided by all of the top experts at Penn Medicine.
Benign Paranasal Sinus Tumors
Benign paranasal sinus tumors are noncancerous tumors that develop in the nose and nasal cavity. We treat and manage many complex benign tumor cases including:
Malignant paranasal sinus tumors are cancerous tumors that develop in the nose and nasal cavity. These types of tumors are extremely rare and it is important that they are treated at a center with a high volume and a large experience. At Penn Rhinology, we work in a multidisciplinary fashion with other skull based surgeons, neurosurgeons, oncologists, radiologists and pathologists to provide comprehensive treatment and care.
To learn more about sinus cancer and tumor types we treat, please visit Abramson Cancer Center.
Personalized Genetics & Penn’s Tumor Tissue Bank
Penn Medicine, in collaboration with The Children’s Hospital of Philadelphia (CHOP), has created a dedicated tumor and gene bank for sinonasal and skull base tumors. Banked tissue can be used in research and clinical trials leading to new and effective treatment options. Patients with banked tissue have the benefit of accessing potential new treatments that can greatly improve their condition and quality of life. Using this data, Penn Cranial Base Surgery will be able to use the genetic profiles of each individual tumor type to target it for treatment, with patient tailored chemotherapy, immunotherapy or other non-surgical treatments. Additionally, should a tumor recur, Penn physicians will be able to screen for new developments in targeted therapy that may allow for new treatments and avoid additional surgeries.